

Amendment to SB 477

1 Amend the bill by replacing all after the enacting clause with the following:

2
3 1 New Paragraph; Use of Cannabis for Therapeutic Purposes; Rules. Amend RSA 126-X:6 by
4 inserting after paragraph III the following new paragraph:

5 IV. The department shall adopt rules relative to the therapeutic cannabis medical oversight
6 board's public hearing process pursuant to RSA 126-X:12, IV.

7 2 New Section; Use of Cannabis for Therapeutic Purposes; Therapeutic Cannabis Medical
8 Oversight Board. Amend RSA 126-X by inserting after section 11 the following new section:

9 126-X:12 Therapeutic Cannabis Medical Oversight Board Established; Membership; Duties.

10 I. There is hereby established the therapeutic cannabis medical oversight board which shall
11 monitor and contribute to the oversight of the clinical, quality, and public health related matters of
12 the use of cannabis for therapeutic purposes under this chapter.

13 II. The board shall consist of the medical director, department of health and human
14 services, or designee, a qualifying patient, appointed by the commissioner of the department, a
15 clinical representative from an alternative treatment center, appointed by the commissioner, and 10
16 medical providers also appointed by the commissioner. The medical provider members shall
17 represent the following fields:

- 18 (a) Neurology.
19 (b) Pain management.
20 (c) Oncology.
21 (d) Psychiatry.
22 (e) Pediatrics.
23 (f) Family or Internal Medicine.
24 (g) Obstetrics and Gynecology.
25 (h) Addiction.
26 (i) Palliative care.
27 (j) Physiatry/orthopedics.

28 III. At its first meeting the board shall elect by majority vote a chairperson and an
29 alternate. A quorum shall consist of a majority of members.

30 IV. The board shall convene at least 2 times per year to monitor and contribute to the
31 oversight of the clinical, quality, and public health related matters of therapeutic cannabis under
32 this chapter by:

Amendment to SB 477
- Page 2 -

1 (a) Reviewing medical and scientific evidence pertaining to currently approved and
2 additional qualifying conditions.

3 (b) Reviewing laboratory results of required testing of cannabis cultivated and/or
4 processed by an alternative treatment center and the use of pesticides on products under RSA 126-
5 X:6, III(a)(16).

6 (c) Monitoring clinical outcomes.

7 (d) Reviewing training protocols for dispensary staff based on models from other states.

8 (e) Receiving updates from alternative treatment centers on effectiveness of various
9 strains, types of cannabinoids, and different routes of administration for specific conditions.

10 (f) Reviewing best practices for medical providers regarding provider education,
11 certification of patients, and patient access to the program.

12 (g) Reviewing any other clinical, quality, and public health related matter relative to
13 use of cannabis under this chapter.

14 V. The board may make recommendations to the commissioner to add or remove qualifying
15 medical conditions under RSA 126-X:1, IX based on the findings pursuant to subparagraph IV(a)
16 and after receiving input from the public through a public hearing process. The commissioner may
17 recommend legislation based on the board's findings.

18 VI. On or before January 1 of each year, the board shall make a report to the president of
19 the senate, the speaker of the house of representatives, the oversight committee on health and
20 human services established under RSA 126-A:13, the board of medicine, the board of nursing, and
21 the therapeutic use of cannabis advisory council established in RSA 126-X:9.

22 3 Effective Date. This act shall take effect 60 days after its passage.

Amendment to SB 477
- Page 3 -

2018-0306s

AMENDED ANALYSIS

This bill establishes the therapeutic cannabis medical oversight board which shall monitor and contribute to the oversight of the clinical, quality, and public health related matters of the use of cannabis for therapeutic purposes law under RSA 126-X.